| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| 100mg | |||
| Other Sizes |
| Targets |
Hexokinase (and glucokinase). D-Mannoheptulose inhibits glucokinases and hexokinases from diverse organisms through competition with D-glucose. It has a Ki of 0.25 mM for inhibition of D-glucose phosphorylation.
|
|---|---|
| ln Vitro |
D-Mannoheptulose is a specific inhibitor of D-glucose phosphorylation by hexokinase isoenzymes. It inhibits glucokinases and hexokinases with a Ki of 0.25 mM. The compound blocks insulin release and carbohydrate utilization in rats. It prevents the conversion of glucose to glucose-6-phosphate.
|
| ln Vivo |
D-Mannoheptulose blocks insulin release and carbohydrate utilization in rats. It is used to study pancreatic beta-cell function, glucose sensing, and energy regulation in vivo. The compound provides insight into carbohydrate metabolism and potential therapeutic strategies for metabolic disorders.
|
| Enzyme Assay |
In vitro enzyme assays for D-Mannoheptulose typically involve measuring hexokinase or glucokinase activity in the presence of varying concentrations of the inhibitor and substrate (D-glucose). Enzyme activity is measured by monitoring the production of glucose-6-phosphate using coupled enzyme assays (e.g., with glucose-6-phosphate dehydrogenase) or by measuring ATP consumption. The Ki value is determined from kinetic analyses.
|
| Cell Assay |
The in vitro cellular activity of D-Mannoheptulose is evaluated in cell lines such as pancreatic beta-cells (e.g., INS-1, MIN6) or hepatocytes. Cells are treated with the compound, and glucose uptake, glucose phosphorylation, insulin secretion, and metabolic flux are measured. The compound's ability to inhibit glucose metabolism and its effects on cellular energy status are assessed.
|
| Animal Protocol |
In vivo animal studies with D-Mannoheptulose typically involve administration to rats via intraperitoneal injection or oral gavage. Endpoints include blood glucose levels, insulin secretion, and carbohydrate utilization. The compound is used to study pancreatic beta-cell function, glucose sensing, and energy regulation. Dosing regimens depend on the specific experimental objectives.
|
| ADME/Pharmacokinetics |
D-Mannoheptulose is a heptose sugar with molecular formula C7H14O7 and molecular weight 210.18. It is a specific inhibitor of D-glucose phosphorylation with a Ki of 0.25 mM. The compound blocks insulin release and carbohydrate utilization in rats. As a sugar, it is expected to have good water solubility and distribution throughout the body.
|
| Toxicity/Toxicokinetics |
No specific toxicological data is available for D-Mannoheptulose. As a naturally occurring sugar found in avocados, it is expected to have relatively low toxicity. However, at high doses, it may cause metabolic disturbances due to its inhibition of glucose metabolism. Standard laboratory safety precautions should be observed.
|
| References | |
| Additional Infomation |
1,3,4,5,6,7-Hexahydroxyheptane-2-one is a heptose. D-Manno-2-heptose has been reported in Hylotelephium spectabile, with relevant data. See also: Crassulacean heptose (note moved to).
D-Mannoheptulose is a 7-carbon keto sugar found in avocados that specifically inhibits D-glucose phosphorylation by hexokinase. It has a Ki of 0.25 mM and blocks insulin release and carbohydrate utilization. It is used as a research tool to study glucose metabolism, pancreatic beta-cell function, and energy regulation. It is not approved for clinical use. |
| Molecular Formula |
C7H14O7
|
|---|---|
| Molecular Weight |
210.18186
|
| Exact Mass |
210.073
|
| CAS # |
3615-44-9
|
| Related CAS # |
D-Mannoheptulose-13C
|
| PubChem CID |
102926
|
| Appearance |
White to off-white solid powder
|
| Density |
1.6±0.1 g/cm3
|
| Boiling Point |
628.0±55.0 °C at 760 mmHg
|
| Melting Point |
151-152ºC
|
| Flash Point |
347.6±28.0 °C
|
| Vapour Pressure |
0.0±4.2 mmHg at 25°C
|
| Index of Refraction |
1.597
|
| LogP |
-2.47
|
| Hydrogen Bond Donor Count |
6
|
| Hydrogen Bond Acceptor Count |
7
|
| Rotatable Bond Count |
6
|
| Heavy Atom Count |
14
|
| Complexity |
183
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
C([C@H]([C@H]([C@@H]([C@@H](C(=O)CO)O)O)O)O)O
|
| InChi Key |
HSNZZMHEPUFJNZ-QMTIVRBISA-N
|
| InChi Code |
InChI=1S/C7H14O7/c8-1-3(10)5(12)7(14)6(13)4(11)2-9/h3,5-10,12-14H,1-2H2/t3-,5-,6-,7+/m1/s1
|
| Chemical Name |
(3S,4S,5R,6R)-1,3,4,5,6,7-hexahydroxyheptan-2-one
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment (e.g. under nitrogen), avoid exposure to moisture. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~100 mg/mL (~475.78 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (11.89 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (11.89 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.5 mg/mL (11.89 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 4.7578 mL | 23.7891 mL | 47.5783 mL | |
| 5 mM | 0.9516 mL | 4.7578 mL | 9.5157 mL | |
| 10 mM | 0.4758 mL | 2.3789 mL | 4.7578 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
